Dynavax Technologies Corporation announced that its experimental shingles vaccine has shown an immune response comparable to that of GSK’s widely used vaccine, Shingrix, in...
BioNTech has reached a significant settlement in its three-year mRNA patent dispute with GSK and CureVac, a fellow German biotechnology firm that BioNTech is...